This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IDRA Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Idera Pharmaceuticals Stock (NASDAQ:IDRA) 30 days 90 days 365 days Advanced Chart Get Idera Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.17▼$7.2352-Week Range N/AVolume21,870 shsAverage Volume464,030 shsMarket Capitalization$450.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. Read More Receive IDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDRA Stock News HeadlinesEnergy Recovery Wins “Breakthrough Innovation Award†at IDRA World CongressDecember 16, 2024 | businesswire.comEkso Bionics (NASDAQ: EKSO)April 11, 2024 | fool.comChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in America could soon begin to replace every single dollar in your bank account… With a better, more technologically advanced dollar… Potentially making a lot of people rich in the process.August 28 at 2:00 AM | Brownstone Research (Ad)Kiniksa PharmaceuticalsNovember 15, 2023 | forbes.comNabriva Therapeutics AG (NBRVF)August 9, 2023 | investing.comMarginaliaApril 26, 2023 | npr.orgNA mysterious rift propels the story in ‘Take What You Need’March 17, 2023 | washingtonpost.comIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookJanuary 18, 2023 | finanznachrichten.deSee More Headlines IDRA Stock Analysis - Frequently Asked Questions How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. When did Idera Pharmaceuticals' stock split? Shares of Idera Pharmaceuticals split before market open on Friday, November 25th 2022.The 2-1 split was announced on Friday, November 25th 2022. The newly minted shares were payable to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX). Company Calendar Last Earnings11/08/2021Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IDRA CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees32Year Founded1989Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$98.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.74% Return on Assets-34.26% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow0.29 Book Value$0.56 per share Price / BookN/AMiscellaneous Outstanding Shares62,355,000Free Float59,206,000Market Cap$450.52 million OptionableOptionable Beta1.25 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IDRA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Idera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access